Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 1;319(1):L39-L44.
doi: 10.1152/ajplung.00183.2020. Epub 2020 Jun 3.

Understanding the age divide in COVID-19: why are children overwhelmingly spared?

Affiliations

Understanding the age divide in COVID-19: why are children overwhelmingly spared?

K Lingappan et al. Am J Physiol Lung Cell Mol Physiol. .

Abstract

The rapid emergence and subsequent global dissemination of SARS-CoV-2 disease (COVID-19) has resulted in over 4 million cases worldwide. The disease has a marked predilection for adults, and children are relatively spared. Understanding the age-based differences in pathophysiological pathways and processes relevant to the onset and progression of disease both in the clinical course and in experimental disease models may hold the key to the identification of therapeutic targets. The differences in the clinical course are highlighted by the lack of progression of the SARS-CoV-2 infection beyond mild symptoms in a majority of children, whereas in adults the disease progresses to acute lung injury and an acute respiratory distress syndrome (ARDS)-like phenotype with high mortality. The pathophysiological mechanisms leading to decreased lung injury in children may involve the decreased expression of the mediators necessary for viral entry into the respiratory epithelium and differences in the immune system responses in children. Specifically, decreased expression of proteins, including angiotensin-converting enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) in the airway epithelium in children may prevent viral entry. The immune system differences may include a relative preponderance of CD4+ T cells, decreased neutrophil infiltration, decreased production of proinflammatory cytokines, and increased production of immunomodulatory cytokines in children compared with adults. Notably, the developing lung in children may have a greater capacity to recover and repair after viral infection. Understanding the relative contributions of the above processes to the protective phenotype in the developing lung can guide the trial of the appropriate therapies in adults.

Keywords: COVID-19; SARS-CoV-2; age-based susceptibility; children; coronavirus; pediatric lung.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest, financial or otherwise, are declared by the authors.

Figures

Fig. 1.
Fig. 1.
Differences in the clinical course in children and adults with SARS-CoV-2 infection: depiction of the general progression of disease and overarching severity of illness among symptomatic adult and pediatric patients. Although the most severe adults progress through the inflammatory phase to profound clinical severity, mild/moderate adults seem to stabilize and recover over a protracted course. Pediatric patients rarely require hospitalization for symptoms and, when more symptomatic early, generally recover quickly. Some children develop a multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. [Adapted in part from Siddiqui et al. (32a), with permission from Elsevier.]
Fig. 2.
Fig. 2.
Mechanisms mediating differential susceptibility of adults and children to COVID-19. Increased expression of mediators essential for viral entry into airway epithelial cells (ACE-2 and TMPRSS2) in adults combined with the proinflammatory milieu in adults may predispose the adult lung to serious pulmonary injury and progression to acute respiratory distress syndrome (ARDS). The pediatric lung has greater expression of immunomodulatory cytokines and possibly a decreased expression of viral entry mediators.

References

    1. Alvira CM, Abate A, Yang G, Dennery PA, Rabinovitch M. Nuclear factor-kappaB activation in neonatal mouse lung protects against lipopolysaccharide-induced inflammation. Am J Respir Crit Care Med 175: 805–815, 2007. doi:10.1164/rccm.200608-1162OC. - DOI - PMC - PubMed
    1. Baas T, Roberts A, Teal TH, Vogel L, Chen J, Tumpey TM, Katze MG, Subbarao K. Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus. J Virol 82: 9465–9476, 2008. doi:10.1128/JVI.00489-08. - DOI - PMC - PubMed
    1. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, Rovida F, Baldanti F, Marseglia GL. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. In press. doi:10.1001/jamapediatrics.2020.1467. - DOI - PubMed
    1. Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T; CDC COVID-19 Response Team . Coronavirus Disease 2019 in Children—United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep 69: 422–426, 2020. doi:10.15585/mmwr.mm6914e4. - DOI - PMC - PubMed
    1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130: 2620–2629, 2020. doi:10.1172/JCI137244. - DOI - PMC - PubMed

Publication types

LinkOut - more resources